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1. Introduction 
Significant progress has been made in demonstrating the role of apoptosis in various heart 
diseases, and in elucidating the molecular mechanisms of cardiac apoptosis. Apoptosis has 
been attributed an essential role in cardiomyopathy. The progressive loss of cardiac 
myocytes is one of the most important pathogenic components of the heart failure. While 
initial studies reported unrealistically high levels of cell death, probably due to 
methodological problems, later work has consistently shown that approximately 80–250 
heart muscle cells per 105 cardiac nuclei commit suicide at any given time in patients with 
late-stage dilated cardiomyopathy. In contrast, the base-line rate of apoptosis in healthy 
human hearts is only one to ten cardiac myocytes per 105 nuclei (Anversa & Kajstura, 1998; 
Yue et al., 1998). Even though the rate of apoptosis in heart failure is relatively low in 
absolute numbers, it is significantly higher than that in the normal heart, which has 
essentially negligible baseline apoptosis. Recently, animal models of heart failure 
incorporating transgenic technology have confirmed that myocyte apoptosis itself is 
sufficient to induce heart failure. Apoptosis has been implicated in a wide variety of 
physiological and pathological processes. The importance of apoptosis in cardiovascular 
system is also becoming increasingly clear, and the inhibition of apoptosis is emerging as a 
potential therapeutic tool for various forms of cardiovascular disease. In this chapter, we 
examine the evidence for apoptosis in cardiovascular disease and the molecular mechanisms 
of cardiac apoptosis. 
2. Apoptosis 
2.1 Concept and morphologic characteristics of apoptosis 
There are two primary pathways by which cells die. The path for accidental cell death is 
called necrosis. Accidental cell death occurs when cells receive a structural or chemical 
insult from which they cannot recover. Examples of such insults include ischemia, 
extremes of temperature, and physical trauma. The hallmark of necrosis is that cells die 
because they are damaged. In contrast, cells that die by programmed cell death commit 
suicide actively as the results of activation of a dedicated intracellular program. For 
programmed cell death, the most commonly described pathway is apoptosis. Apoptosis 
begins with a signal that can come from within the cell (e.g., detection of radiation-
induced DNA breaks) or from without (e.g., a decrease in the level of an essential growth 
factor or hormone). This pro-apoptotic signal induces the cell to make a decision to 
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commit suicide. Initially, cells that are committed to undergo programmed cell death are 
in a latent phase of apoptosis. The latent phase can be subdivided into two stages: a 
condemned stage, during which the cell is proceeding on a pathway toward death but can 
still be rescued if it is exposed to anti-apoptotic activities, and a committed stage, beyond 
which rescue is impossible. Ultimately, the cells enter the execution phase of apoptosis, in 
which they undergo the dramatic morphologic and physiological changes (Pollard & 
Earnshaw, 2004). Apoptosis is characterized by a reproducible pattern of structural 
alterations of both the nucleus and cytoplasm. In order of appearance, these include: (1) 
Loss of microvilli and intercellular junctions. (2) Shrinkage of the cytoplasm. The cell is 
smaller in size. The cytoplasm is dense. The organelles, although relatively normal, are 
more tightly packed. (3) Dramatic changes in cytoplasmic motility with activation of a 
violent program of blebbing. (4) Loss of plasma membrane asymmetry, with the 
distribution of phosphatidyl serine being randomized so that it appears in the outer 
membrane leaflet. (5) Changes in the organization of the cell nucleus, typically involving 
the hypercondensation of the chromatin. This is the most characteristic feature of 
apoptosis. The chromatin aggregates peripherally, under the nuclear membrane, into 
dense masses of various shapes and sizes. The nucleus itself may break up, producing two 
or more fragments. (6) Formation of cytoplasmic blebs and apoptotic bodies. The 
apoptotic cell first shows extensive surface blebbing, then undergoes fragmentation into 
membrane-bound apoptotic bodies composed of cytoplasm and tightly packed organelles, 
with or without nuclear fragments.  (7) Phagocytosis of apoptotic cells or cell bodies, 
usually by macrophages. The apoptotic bodies are rapidly degraded within lysosomes, 
and the adjacent healthy cells migrate or proliferate to replace the space occupied by the 
now deleted apoptotic cell. Because the vesicles remain membrane bound, the cellular 
contents are never released into the environment. As a result, apoptotic death does not 
lead to an inflammatory response. (Kumar et al., 2005; Pollard & Earnshaw, 2004).  
2.2 Molecular mechanism and pathway description 
The process of apoptosis may divided into an initiation phase, during which caspases 
become catalytically active, and an execution phase, during which these enzymes act to 
cause cell death. Initiation of apoptosis occurs principally by signals from two distinct but 
convergent pathways: the extrinsic, or receptor-initiated, pathway and the intrinsic or 
mitochondrial pathway. Both pathways converge to activate caspases and they may be 
interconnected at numerous steps.  
2.2.1 The extrinsic (death receptors) pathway 
This pathway is initiated by engagement of cell surface death receptors on a variety of cells. 
Death receptors are members of the tumor necrosis factor receptor family (Fas, TNFǂR, DR3, 
DR4, DR5) that contain a cytoplasmic domain involved in protein-protein interactions that is 
called death domain because it is essential for delivering apoptotic signals.. Death receptor 
ligands characteristically initiate signaling via receptor oligomerization, which in turn 
results in the recruitment of specialized adaptor proteins and activation of caspase cascades. 
Binding of FasL induces Fas trimerization, which recruits initiator caspase-8 via the adaptor 
protein FADD. Caspase-8 then oligomerizes and is activated via autocatalysis. Activated 
caspase-8 stimulates apoptosis via two parallel cascades: it can directly cleave and activate 
caspase-3, or alternatively, it can cleave Bid, a pro-apoptotic Bcl-2 family protein. Truncated 
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Bid (tBid) translocates to mitochondria, inducing cytochrome c release, which sequentially 
activates caspase-9 and -3. TNF-ǂ and DR-3L can deliver pro- or anti-apoptotic signals. 
TNFǂR and DR3 promote apoptosis via the adaptor proteins TRADD/FADD and the 
activation of caspase-8. Interaction of TNF-ǂ with TNFǂR may activate the NF-κB pathway 
via NIK/IKK. The activation of NF-κB induces the expression of pro-survival genes 
including Bcl-2 and FLIP, the latter can directly inhibit the activation of caspase-8. Some 
viruses and normal cells produce FLIP, which binds to pro-caspase-8 but cannot cleave and 
activate the enzyme because it lacks enzymatic activity, and use this inhibitor to protect 
infected and normal cells from Fas-mediated apoptosis (Kumar et al., 2005). FasL and TNF-ǂ 
may also activate JNK via ASK1/MKK7. Activation of JNK may lead to the inhibition of Bcl-
2 by phosphorylation. In the absence of caspase activation, stimulation of death receptors 
can lead to the activation of an alternative programmed cell death pathway termed 
necroptosis by forming complex IIb. (Humphreys & Halpern, 2008; Logue & Martin, 2008; 
Yuan, 2010) 
2.2.2 The intrinsic (mitochondrial) pathway 
This pathway of apoptosis is the result of increased mitochondrial permeability and release 
of pro-apoptotic molecules into the cytoplasm, without a role for death receptors. Growth 
factors and other survival signals stimulate the production of anti-apoptotic members of the 
Bcl-2 family of proteins. The Bcl-2 family of proteins regulates apoptosis by controlling 
mitochondrial permeability. The anti-apoptotic proteins Bcl-2 and Bcl-xL reside in the outer 
mitochondrial wall and inhibit cytochrome c release. The proapoptotic Bcl-2 proteins Bad, 
Bid, Bax, and Bim may reside in the cytosol but translocate to mitochondria following death 
signaling, where they promote the release of cytochrome c. Bad translocates to mitochondria 
and forms a pro-apoptotic complex with Bcl-xL. This translocation is inhibited by survival 
factors that induce the phosphorylation of Bad, leading to its cytosolic sequestration. 
Cytosolic Bid is cleaved by caspase-8 following signaling through Fas; its active fragment 
(tBid) translocates to mitochondria. Bax and Bim translocate to mitochondria in response to 
death stimuli, including survival factor withdrawal. Activated following DNA damage, p53 
induces the transcription of Bax, Noxa, and PUMA. Upon release from mitochondria, 
cytochrome c binds to Apaf-1 and forms an activation complex with caspase-9. Although the 
mechanism(s) regulating mitochondrial permeability and the release of cytochrome c during 
apoptosis are not fully understood, Bcl-xL, Bcl-2, and Bax may influence the voltage-
dependent anion channel (VDAC), which may play a role in regulating cytochrome c 
release. Mule/ARF-BP1 is a DNA damage activated E3 ubiquitin ligase for p53, and Mcl-1, 
an anti-apoptotic member of Bcl-2 (Brenner & Mak, 2009; Chalah & Khosravi-Far, 2008; 
Yuan 2010). The essence of this intrinsic pathway is a balance between pro-apoptotic and 
protective molecules that regulate mitochondrial permeability and the release of death 
inducers that are normally sequestered within the mitochondria (Kumar et al., 2005). 
2.2.3 The execution phase 
The final phase of apoptosis is mediated by a proteolytic cascade, toward which the various 
initiating mechanisms converge. Caspases, a family of cysteine proteases, are the central 
regulators of apoptosis. They are mammalian homologues of the ced-3 in the nematode 
Caenorhabditis elegans. The caspase family, now including more than 10 members, can be 
divided functionally into two basic groups – initiator and executioner – depending on the 
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order in which they are activated during apoptosis. Caspases exist as inactive pro-enzymes, 
or zymogens, and must undergo an activating cleavage for apoptosis to be initiated. 
Caspases have their own cleavage sites that can be hydrolyzed not only by other caspases 
but also autocatalytically. After an initiator caspase is cleaved to generate its active form, the 
enzymatic death program is set in motion by rapid and sequential activation of other 
caspases. Executioner caspases act on many cellular components. They cleave cytoskeletal 
and nuclear matrix proteins and thus disrupt the cytoskeleton and lead to breakdown of the 
nucleus. In the nucleus, the targets of caspase activation include proteins involved in 
transcription, DNA replication, and DNA repair (Haunstetter & Izumo, 1998; Kumar et al., 
2005) (Table 1). Initiator caspases (including caspase-2, -8, -9, -10, -11, and -12) are closely 
coupled to pro-apoptotic signals. Once activated, these caspases cleave and activate 
downstream effector caspases (including caspase-3, -6, and -7), which in turn execute 
apoptosis by cleaving cellular proteins following specific Asp residues. Activation of Fas 
and TNFR by FasL and TNF, respectively, leads to the activation of caspase-8 and -10. DNA 
damage induces the expression of PIDD which binds to RAIDD and caspase-2 and leads to 
the activation of caspase-2. Cytochrome c released from damaged mitochondria is coupled 
to the activation of caspase-9. XIAP inhibits caspase-3, -7, and -9. Mitochondria release 
multiple pro-apoptotic molecules, such as Smac/ Diablo, AIF, HtrA2 and EndoG, in 
addition to cytochrome c. Smac/Diablo binds to XIAP which prevents it from inhibiting 
caspases. Caspase-11 is induced and activated by pathological proinflammatory and pro-
apoptotic stimuli and leads to the activation of caspase-1 to promote inflammatory response 
and apoptosis by directly processing caspase-3. Caspase-12 and caspase-7 are activated 
under ER stress conditions. Anti-apoptotic ligands including growth factors and cytokines 
activate Akt and p90RSK. Akt inhibits Bad by direct phosphorylation and prevents the 
expression of Bim by phosphorylating and inhibiting the Forkhead family of transcription 
factors (Fox0). Fox0 promotes apoptosis by upregulating pro-apoptotic molecules such as 
FasL and Bim (Degterev & Yuan, 2008; Kurokawa & Kornbluth, 2009; Yuan 2010). 
 
Nuclear proteins 
Lamin, Rb protein, DNA-dependent protein kinase, 70-kDa subunit of U1 small nuclear 
ribonucleoprotein, Poly (ADP)-ribosylating protein (PARP), Mdm2 
Regulatory proteins 
MAPK/ERK kinase kinase 1 (MEKK1), Protein Kinase Cδ, G4-GDI GDP dissociation 
inhibitor, Sterol regulatory element binding protein, DNA fragmentation factor/inhibitor 
of caspase-activated DNAse 
Cytoskeletal proteins 
Fodrin, Gelsolin, Actin, Gas2 
Table 1. Downstream targets of Caspases. (Haunstetter & Izumo, 1998) 
2.3 Study of apoptosis 
Light and electron microscopy are two of the classical techniques for the study of this 
process. Because of the lack of cellular synchronization in apoptosis and of the fact that the 
apoptotic cell is rapidly disposed of through phagocytosis, study methods based on 
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morphologic criteria are adequate for the demonstration of the process, but are not useful 
for quantifying it. Further to these procedures, the study of DNA fragmentation in agarose 
gels has been considered to be identificative for apoptosis. A number of techniques take 
advantage of this DNA fragmentation for labelling the fragments and thus for quantifying 
the proportion of apoptotic cells. Each DNA fragment has a 3'OH terminal portion. This 
terminal fragment can be labelled in various ways (for instance, with the help of a modified 
terminal deoxynucleotidyl transferase), so that the labelling rate is proportional to the 
degree of DNA fragmentation. In TUNEL assay (terminal deoxyribonucleotidyl transferase 
[TdT]-mediated dUTP-digoxigeninnick end labeling), TdT transfers a fluorescent nucleotide 
to exposed breakpoints of DNA. Apoptotic cells that have incorporated the labeled 
nucleotide are then visualized by fluorescence microscopy or flow cytometry. Apoptotic 
cells that have extruded some of the DNA have less than their normal diploid content. 
Automated measurement of the amount of DNA in individual cells by flow cytometry thus 
produces a population distribution according to DNA content (cytofluorograph) (Rubin et 
al., 2005). At present, the most widely accepted and standardized technique takes advantage 
of the changes in the membrane phospholipids that occur early in apoptotic cells (Vermes et 
al., 1995). The negatively charged membrane phospholipids exposed to the external 
environment by the apoptotic cell are labeled with fluorochrome-conjugated molecules, and 
the percentage of fluorescent cells can be easily quantified (Chamond et al., 1999). 
2.4 Apoptosis in developmental and physiological processes  
Cell death is extremely important in embryonic development, maintenance of tissue 
homeostasis, establishment of immune self-tolerance, killing by immune effector cells, and 
regulation of cell viability by hormones and growth factors. Apoptosis is a normal 
phenomenon that serves to eliminate cells that are not longer needed and to maintain a 
steady number of various cell populations in tissues. It is important in the following 
physiologic situations. During molecular maturation of T-cell antigen receptors, immature T 
cells in the thymus rearrange the genes encoding the receptor ǂ and ǃ chains. Cells with 
receptors recognizing self-antigens are potentially harmful and are eliminated through 
programmed cell death. Cells with damaged DNA tend to accumulate mutations, and they 
are potentially harmful to the organism. DNA damage induces programmed cell death in 
many cell types.  Furthermore one of the mechanisms to eliminate infected cells is through 
the action of cytotoxic T lymphocytes, which kill cells, by inducing them to undergo 
programmed cell death. T lymphocytes whose T-cell receptors cannot interact with the 
spectrum of MHC glycoproteins expressed in a given individual are ineffective in the 
immune response. Up to 95% of immature T cells die by apoptosis without leaving the 
thymus.  Fetal development involves the sequential appearance and regression of many 
anatomical structures: some aortic arches do not persist, the mesonephros regresses in favor 
of the metanephros, interdigital tissues disappear to allow discrete fingers and toes, and 
excess neurons are pruned from the developing brain. Cells in these conditions serve no 
purpose in humans and are eliminated by programmed cell death. Excess neurons that do 
not make appropriate connections have no function and so are eliminated by apoptosis. Up 
to 80%of neurons in certain developing ganglia die this way (Rubin et al., 2005). Apoptosis 
also eliminates the constituent cells of mullerian ducts in males. Epithelial cells must die to 
allow fusion of palate and mammary and prostate cells die when deprived of hormones 
(Pollard & Earnshaw, 2004). 
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2.5 Apoptosis and disease 
Death by apoptosis is also responsible for loss of cells in a variety of pathologic states. The 
diseases in which apoptosis has been involved can be divided into two groups: those in 
which there is an increase in cell survival (or diseases associated to inhibition of apoptosis), 
and those in which there is an increase in cell death (and hence hyperactive apoptosis) 
(Chamond et al., 1999). The group of diseases associated to apoptosis inhibition includes 
those diseases in which an excessive accumulation of cells occurs (neoplastic diseases, 
autoimmune diseases) (Table 2). It was classically believed that the excessive accumulation 
of cells in these diseases occurred because of an increased cell proliferation. In recent years, 
the study of apoptosis in these patients has led to a new and different approach, according 
to which this accumulation of cells would be due to defective apoptosis. Increased cell 
apoptosis has also been implicated in the aetiopathogenesis of a number of diseases. 
A large group of neurodegenerative diseases, among them Alzheimer's disease, Parkinson's 
disease, amyotrophic lateral sclerosis and retinitis pigmentosa, are associated to selective 
apoptosis of the neurones. This neuronal death appears to be associated to increases 
susceptibility to apoptosis in these cells. Oxidative stress, mitochondrial defects and 
neurotoxic agents have been postulated as the inductors of neuronal death. The disease 
associated to infection by the Human Immunodeficiency Virus (HIV) has been defined as an 
imbalance between the number of CD4+ lymphocytes and the ability of the bone marrow to 
generate new mature cells. The CD4+ cells of the HIV(+) patients die through apoptosis 
when stimulated in vitro. Also, HIV infection of cells from healthy subjects induces 
apoptosis of CD4+ cells. However, further to this, not only the infected cells but also non-
infected cells undergo apoptosis. Replicative exhaustion of the responding cell clones has 
been demonstrated in a number of diseases (among them AIDS, in which the responding 
clone is the CD4+ one); in these diseases the responding clone, after an initial phase of 
intense response to the stimulus, become exhausted and undergo apoptosis (Ameisen, 1995). 
 
Through inhibition of apoptosis Through excess apoptosis 
Cancer 
Colorectal  
Glioma  
Hepatic  
Neuroblastoma  
Leukaemias and lymphomas  
Prostate 
Autoimmune diseases 
Myastenia gravis  
Systemic lupus erythematosus 
Inflammatory diseases 
Bronchial asthma  
Inflammatory intestinal disease  
Pulmonary inflammation 
Viral infections 
Adenovirus  
Baculovirus 
AIDS 
T lymphocytes 
Neurodegenerative diseases 
Alzheimer’s disease  
Amyotrophic lateral sclerosis  
Parkinson’s disease  
Retinitis pigmentosa  
Epilepsy 
Haematologic diseases 
Aplastic anaemia  
Myelodysplastic syndrome  
T CD4+ lymphocytopenia  
G6PD deficiency 
Tissue damage 
Myocardial infarction  
Cerebrovascular accident  
Ischaemic renal damage  
Polycystic kidney 
Table 2. Diseases associated to apoptosis 
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2.6 Apoptosis and cardiovascular disease 
The myocardial cells allocate a limited faculty of proliferation and correspondingly, 
apoptosis is observed infrequently in adult hearts. On the contrary at the duration of 
organogenesis and in the formation of heart the apoptosis plays an important role, as an 
example in the formation of septa between the cardiac chambers and the valves. As 
consequence the defects in apoptosis can constitute basic causative factor of relatives of 
congenital heart disease. Apoptosis of myocardial cells is also observed afterwards the 
birth and concretely in the interventricular septum and right ventricular wall, at the 
duration of passage from the fetal circulation in the adult circulation. Moreover the 
phenomenon of apoptosis is also distinguished in the conducting system and can lead to 
congenital heart block, syndrome of long QT, and the existence of accessory pathways 
(Table 3) (Bennett, 2002). Until recently, the loss of myocytes was attributed to necrosis; 
however, it is now clear that apoptosis may play an important role in the pathogenesis of 
a variety of cardiovascular diseases. For instance, apoptosis has been detected in 
myocardial samples obtained from patients with end-stage congestive heart failure, 
arrhythmogenic right ventricular dysplasia and myocardial infraction. In addition, 
apoptosis has been detected in cardiac myocytes under hypoxia/reoxygenetion, 
mechanical stretch and in animal models of cardiac ischemia/reperfusion injury (Table 4) 
(Gustafsson & Gottlieb, 2003). 
 
 
 
 
Myocyte 
Idiopathic dilated cardiomyopathy 
Ischaemic cardiomyopathy 
Acute myocardial infarction 
Arrhythmogenic right ventricular dysplasia 
Myocarditis 
Conducting tissues 
Pre-excitations syndromes 
Congenital complete atrioventricular heart 
Long QT syndromes 
Vascular 
Atherosclerosis 
Restenosis after angioplasty / stenting 
Vascular graft rejection 
Arterial aneurysm formation 
 
 
 
 
 
Table 3. Apoptosis and cardiovascular disease (Bennett, 2002; Haunstetter & Izumo, 1998) 
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Stimulus Signaling pathway Potential inhibitor 
Ischaemia/reperfusion 
Pressure overload 
Neurohormonal 
factors 
Ischaemia 
Death receptor ligands 
ERK/SARK 
ERK/SARK 
G protein coupling 
Lack of growth factor 
signaling 
Adapter molecules / 
caspases 
Activation of ERK, inhibition of SARK 
signaling 
Activation of ERK, inhibition of SARK 
signaling 
ǃ blockers 
Activation of Akt/ERK pathways 
Decoy receptors / receptor 
antagonists 
IAPs / caspase inhibitors 
ERK, extracellular signal related kinase; IAP, inhibitor of apoptosis protein; SAPK, stress 
activated protein kinase 
Table 4. Potential inhibitors and signaling pathways of cardiomyocyte apoptosis (Bennett, 
2002). 
2.6.1 Apoptosis and atherosclerosis 
Apoptosis constitutes basic characteristic of vessels remodeling that takes place in 
organogenesis and in pathological situations like injury and atherosclerosis. The 
significance of apoptosis in atherosclerosis depends on the stage of the plaque, 
localization and the cell types involved. Apoptosis of vascular smooth muscle cells (SMC), 
endothelial cells and macrophages may promote plaque growth and pro-coagulation and 
may induce rupture, the major consequence of atherosclerosis in humans. Apoptosis of 
macrophages is mainly present in regions showing signs of DNA synthesis/repair. SMC 
apoptosis is mainly present in less cellular regions and is not associated with DNA 
synthesis/repair. Even in the early stages of atherosclerosis SMC become susceptible to 
apoptosis since they increase different pro-apoptotic factors. Moreover, recent data 
indicate that SMC may be killed by activated macrophages.  The loss of the SMC can be 
detrimental for plaque stability since most of the interstitial collagen fibres, which are 
important for the tensile strength of the fibrous cap, are produced by SMC. Rupture of 
atherosclerotic plaques is associated with a thinning of the SMC-rich fibrous cap 
overlying the core. Rupture occurs particularly at the plaque shoulders, which exhibit lack 
of SMCs and the presence of inflammatory cells. Apoptotic SMCs are evident in advanced 
human plaques including the shoulders regions, prompting the suggestion that SMC 
apoptosis may hasten plaque rupture. Indeed, increased SMC apoptosis occurs in 
unstable versus stable angina lesions. Apoptosis of macrophages could be beneficial for 
plaque stability if apoptotic bodies were removed. Apoptotic cells that are not scavenged 
in the plaque activate thrombin, which could further induce intraplaque thrombosis 
(Kockx & Knaapen, 2000). Most apoptotic cells in advanced lesions are macrophages next 
to the lipid core. Loss of macrophages from atherosclerotic lesions would be predicted to 
promote plaque stability rather than rupture, since macrophages can promote SMC 
apoptosis by both direct interactions and by release of cytokines (Bennett, 2002). It can be 
concluded that apoptosis in primary atherosclerosis is detrimental since it could lead to 
plaque rupture and thrombosis.  
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2.6.2 Apoptosis and ischaemia/infarction 
Cardiac myocyte death during ischemic injury has been thought to occur exclusively by 
necrosis, but recently several studies have demonstrated that large numbers of myocytes 
undergo apoptosis in response to ischemic disorders (Saraste et al., 1997).  In humans, 
apoptosis seems to occur primarily in the border zone of the ischemic region and, according 
to some studies, in the remote from ischemia regions. However, in vivo animal studies have 
demonstrated apoptosis both in the ischemic region and the ischemic border zone. 
Apoptosis of cardiomyocytes occurs in a temporally and spatially specific manner.  The 
central, unperfused region also manifests apoptosis, particularly within the first six hours, 
although between 6-24 hours necrosis is more common (Bennett, 2002). In contrast, in some 
studies ischemia caused apoptosis in the ischemic region alone, whereas reperfusion caused 
a decrease in apoptotic cells in the ischemic region and an increase in apoptotic cells in the 
ischemic border zone and the remote from ischemia regions. These differences theoretically 
could be explained by the different methods of measuring apoptosis that were used (Krijnen 
et al., 2002). Apoptosis in the remote non-infarcted myocardium may be partly responsible 
for myocardial remodelling and dilatation after myocardial infarction, and may be amenable 
to treatment.  Apoptosis is a highly regulated process in which several regulatory proteins 
play a significant part. P53 limits cellular proliferation by inducing cell cycle arrest and 
apoptosis in response to cellular stresses such as DNA damage, hypoxia, and oncogene 
activation. P53 mediates apoptosis through a linear pathway involving bax activation, 
cytochrome c release from mitochondria, and caspase activation (Shen & White, 2001). The 
Bcl-2 family of proteins constitutes a critical checkpoint in cell death. These proteins contain 
agonists and antagonists of apoptosis and alterations of their ratio determine the life or 
death of a cell (Anversa & Kajstura, 1998). Proapoptotic proteins include Bax, Bak, Bad, and 
Bcl-xs whereas Bcl-2 and Bcl-xL are antiapoptotic. Several studies have demonstrated that 
Bcl-2 protein is induced in salvaged myocytes surrounding infracted areas in the regions at 
risk in acute stage of infraction. Bcl-2 positive myocytes were not seen in the infracted 
myocytes in the heart with acute infraction. Bcl-2 positive immunoreactivity was not evident 
in salvaged myocytes of hearts with old infraction, in chronic ischemic disease or in normal 
hearts. P53 and Bax protein expression was rare in salvaged myocytes within the risk area at 
the acute stage of infraction. P53 and Bax positive immunoractivity was evident in the 
infracted myocytes. P53 protein is induced in salvaged myocytes at the old stage of 
infraction and in chronic ischemic disease. P53 positive immunoreactivity of normal control 
heart tissue was slight in most of myocytes. Myocytes exposed to various stress, such as 
chronic ischemia (salvaged myocytes at the old stage of infraction, myocytes at chronic 
ischemic disease) induced the overexpression of p53 protein (Tsipis et al., 2007). 
Consequently, the expression of bcl-2 or P53 protein in myocytes of human hearts with 
infarction may play an important role in the protection or the acceleration of cellular 
damage after infarction (Figure 1, Figure 2). 
2.6.3 Apoptosis and heart failure 
Congestive heart failure occurs as a late manifestation in diverse cardiovascular diseases 
characterized by volume or pressure overload and significant loss of contractile muscle mass. 
Cardiac output is initially maintained in these disorders by the development of compensatory 
myocardial hypertrophy and dilatation. However, the early mechanical adaptations to growth 
stimulus soon fall short of adequate compensation. The mechanism by which compensatory  
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Fig. 1. Immunohistochemical staining for Bcl-2 in myocardial infarction (X400). 
 
 
 
 
 
Fig. 2. Immunohistochemical staining for P53 in myocardial infarction (X400). 
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response triggered by myocardial failure culminates in myocardial dysfunction is not 
clear.  In the past few years, several scientists have proposed apoptosis as the basis of the 
inexorable decline in ventricular systolic function (Narula et al., 2000). Although the 
initial studies reported unrealistically high levels of apoptosis in failed heart (as much as 
35%), recent studies show an apoptosis rates of <1% (TUNEL-positive cells) during heart 
failure (Kang & Izumo, 2000). Because of the limitations with TUNEL staining and the 
difficulties in interpreting these findings, the use of TUNEL alone to detect the presence of 
apoptosis is not sufficient to define the role of apoptosis in heart failure. Later studies 
have consistently shown that approximately 80–250 heart muscle cells per 105 cardiac 
nuclei commit suicide at any given time in patients with late-stage dilated 
cardiomyopathy. In contrast, the base-line rate of apoptosis in healthy human hearts is 
only one to ten cardiac myocytes per 105 nuclei (Anversa & Kajstura, 1998; Yue et al., 
1998). Even though the rate of apoptosis in heart failure is relatively low in absolute 
numbers, it is significantly higher than that in the normal heart, which has essentially 
negligible baseline apoptosis. Recently, animal models of heart failure incorporating 
transgenic technology have confirmed that very low levels of myocyte apoptosis, levels 
that are four- to tenfold lower than those seen in human heart failure, are sufficient to 
cause a lethal, dilated cardiomyopathy (Wencker et al., 2003).   
It has been long believed that apoptosis does not occur in terminally differentiated cells such 
as adult cardiomyocytes. However, all mechanisms responsible for induction of apoptosis 
are operative in myocytes and are particularly activated during heart failure. Actually, the 
onset of myocardial failure leads to systemic and myocardial neurohumoral alterations and 
cytokine expression to maintain cardiac output. Upregulation of these adaptive responses 
also induces growth response and leads to compensatory myocardial hypertrophy and 
dilatation. Cardiac myocytes differentiate and withdraw from the cell cycle during the 
neonatal period, and persistent growth stimulus in the adult myocardium (such as that in 
heart failure) is perceived as a contradictory genetic demand, and programmed cell death 
occurs (Narula et al., 2000). P53 (tumor suppressor protein) is involved in the regulation of 
cell cycle progression in response to DNA damage. This p53 typically causes the cell to 
delay its entry into S phase until the damage has been repaired. P53 also is involved in 
triggering an apoptotic response in instances in which the damage is too severe to repair. 
P53 is a transcriptional regulator of the bcl-2 and bax genes. P53 mediates apoptosis through 
a linear pathway involving bax transactivation, Bax translocation from the cytosol to 
membranes, cytochrome c release from mitochondria, and caspase-9 activation, followed by 
the activation of caspase-3, -6, and -7 (Kim et al., 1994; Shen & White, 2001). P53 down-
regulates the antiapoptotic gene product Bcl-2 and up-regulates the proapoptotic gene 
product Bax. Immunohistochemistry of p53 and antiapoptotic Bcl-2 protein demonstrated 
higher levels of both of these proteins in heart failure as compared with normal hearts 
(Figure 3, Figure 4). Tsipis et al. have observed that the percentage of p53- and bcl-2 positive 
samples in the end-stage dilated cardiomyopathy was 100% (20/20 diseased group samples). 
A 2- and 2.5-fold increase in p53 and bcl-2 positive samples was observed in the diseased 
group as compared with the control group. The diseased group had a larger number of 
samples with strong p53 staining as compared with the control group, which demonstrated 
weak p53 staining. Bcl-2 staining in the positive samples of the diseased group was 
generally weak as in the control group (Tsipis et al., 2010). Latif and colleagues, in a 
quantitation of the bcl-2 family of proteins after Western Immunoprobing, demonstrated  
a 2.9- and 5.35-fold increase in the levels of Bax and of Bcl-2, respectively, 
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Fig. 3. Immunohistochemical staining for p53 protein in dilated cardiomyopathy (X400). 
 
 
 
 
 
Fig. 4. Immunohistochemical staining for bcl-2 in dilated cardiomyopathy (X400). 
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in patients with dilated cardiomyopathy (Latif et al., 2000). Narula and colleagues 
demonstrated a release of cytochrome c from mitochondria in patients with heart failure 
(Narula et al., 2000). In the study of Tsipis et .al, increased expression of P53 protein was 
seen, but p53 up-regulates the proapoptotic gene product Bax (Tsipis et al., 2010). 
Elevated levels of Bax and Bak may mediate the release of cytochrome c, as it has been 
demonstrated that Bax and Bak accelerate the opening of the voltage-dependent anion 
channel (Latif et al., 2000; Shimizu et al., 1999). These results suggest that increased 
expression of p53 may be associated with apoptosis in heart failure of end-stage dilated 
cardiomyopathy. Moreover, various factors present in the failing myocardium have been 
shown to stimulate apoptosis in cardiac myocytes. Such factors include inflammatory 
cytokines, reactive oxygen species, nitric oxide, hypoxia, reperfusion, growth factors, and 
mechanical stretch (Foo et al., 2005). Ventricular decompensation and failure impose an 
elevated diastolic load on myocytes, resulting in stretching of sarcomeres and the 
stimulation of multiple second messenger systems which have been linked to the 
initiation of myocyte reactive hypertrophy in the pathologic heart. Abnormal levels of 
resting tension may lead to the local release of angiotensin II (Ang II) and the induction of 
programmed cell death in the myocardium. Sarcomere elongation in vitro results in Ang II 
release and activation of p53 and p53-dependent genes (Leri et al., 1998). Moreover, 
overstretching appears to be coupled with oxidant stress, expression of Fas, programmed 
cell death, architectural rearrangement of myocytes, and impairment in force 
development of the myocardium (Cheng et al., 1995). Using Western blotting, Olivetti et 
al. demonstrated a 2.4-fold increase in bcl-2 in patients with heart failure (Olivetti et al., 
1997). However, the expression of Bax protein was not altered in the diseased group. This 
low expression of Bax protein may represent the prevalence of bcl-2 compensatory 
mechanism. The elevated presence of p53-positive cells, as demonstrated by 
immunohistochemistry, suggest that apoptosis may be significantly higher in dilated 
cardiomyopathy than that in the normal heart. On the other hand, increased expression of 
the antiapoptotic protein bcl-2 in human myocardium with dilated cardiomyopathy may 
be a compensation for the loss of myocytes and a possible compensatory antiapoptotic 
mechanism in the diseased group (Tsipis et al., 2010). In conclusion the etiology of heart 
failure in dilated cardiomyopathy involves multiple agents. The heart failure involves not 
only the contractile dysfunction, but also the progressive loss of myocytes by apoptosis. 
The elevated expression of proapoptotic is associated with progressive loss of myocytes in 
heart failure, and the increased expression of antiapoptotic proteins represent a possible 
compensatory mechanism. The prevalence of the apoptotic mechanism or this of 
compensatory antiapoptotic may influence the evolution of heart failure in 
cardiomyopathy. 
3. Conclusions 
Cells are poised between survival and apoptosis, and their fate rests on a balance of 
powerful intracellular and extracellular forces, whose signals constantly act upon and 
counteract each other. In many circumstances, apoptosis is a self-protective programmed 
mechanism that leads to the suicide of a cell when its survival is deemed detrimental to 
the organism. In other instances, apoptosis is a pathological process that contributes to 
many disorders. Thus, the pharmacological manipulation of apoptosis represents an 
active frontier of drug development. Recognition of the inducing mechanisms of 
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apoptosis could open up ways to inhibit cell death in cardiovascular tissues and possibly 
help to define targets for future drug design. Furthermore, end-stage events of apoptosis, 
such as the activation of downstream caspases are essentially uniform in all cell types; 
although some regulatory mechanisms may be unique to cells in cardiovascular tissues. 
Elucidation of proapoptotic and antiapoptotic mechanisms in cardiomyocytes and 
vascular smooth muscle cells could delineate potential targets for intervention. In 
conclusion, various factors present in the diseased myocardium have been shown to 
stimulate apoptosis in cardiac myocytes. Changes in the induction of genes promoting or 
opposing apoptosis may modulate the total amount of myocyte damage. There is still a 
need to clarify the role played by different genetic and environmental factors implicated 
in cell death or survival. 
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